drugset / Trial / NCT03845387

A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.

NCT03845387

Phase 2 Completed 74 enrolled Kissei Pharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

Objective of this study is to investigate the efficacy, safety and pharmacokinetics of KDT-3594 in patients with early Parkinson's disease without a concomitant medication of L-dopa.

Timeline

Start
2019-02-26
Primary completion
2020-02-21
Completion
2020-02-21

Drugs

EvaluationDrugModalityDoseRoute
Subject KDT-3594 Unknown Oral
Subject Pramipexole Unknown Oral

Indications